Brand name: ALIJI-3
Composition:
Each tablet contains:
Sofosbuvir…………………………………..400mg
Velpatasvir…………………………………..100mg
Indications:
Suitable for treating chronic HCV genotype 1, 2, 3, 4, 5, or 6 infections in adults and children aged 3 and above:
• Without cirrhosis or with compensated cirrhosis
• With decompensated cirrhosis for use in combination with ribavirin
Dosage:
• Oral, once a day, one tablet each time, for 12 weeks. When used in combination with ribavirin, please also refer to the prescription information of drugs containing ribavirin.
• The drug can be taken with or without food.
Contraindications:
• Patients who are allergic to any component of this product.
Warnings:
- The risk of hepatitis B virus reactivation in patients with co infection of HCV and HBV.
- It is not recommended to use this product in combination with amiodarone as there is a risk of symptomatic bradycardia.
- It is not recommended to use in combination with potent P-gp inducers and potent CYP inducers.
- When used in combination with ribavirin, refer to the warnings and precautions of ribavirin.
- Pregnant and lactating women should use it with caution.
Adverse Effects:
• Headache, fatigue, nausea, anemia, insomnia, etc.
Dosage form: Pink tablet.
Expiry date: 24 months after date of manufacture.
Packaging:
• 28 tablets/bottle.
Storage:
• Protected from light, sealed, and stored at 20℃- 25℃.
• Keep out of reach of children.
DISCLAIMER
The information on this website about our medications is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay seeking care because of something you have read on this website.
For your safety:
Do not self-diagnose or treat any medical condition based solely on the information on this website. If you have any questions or concerns about a medication, please talk to your doctor or pharmacist.
